This is a ready-to-use plan for running a formulation development program from early excipient screening through a locked, transferable formulation, stage-gated so the presentation decision, liquid, frozen, or lyophilized, is made from measured data rather than habit. Replace every <<FILL: ...>> placeholder with your own specifics, set your document numbers and dates, and route it through your normal document control, review, and approval. A worked filled specimen follows the template. Verify each cited reference against the current source before you rely on it.
Document control header
| Field | Entry |
|---|---|
| Document title | Formulation Development Plan for <<FILL: product>> |
| Document number | <<FILL: e.g. FDP-2026-03>> |
| Version | <<FILL>> |
| Effective date | <<FILL>> |
| Modality | <<FILL: protein / oligonucleotide (naked or LNP) / cell / viral vector (AAV)>> |
| Development stage entering this plan | <<FILL: early screening / lead selection / presentation lock / late-stage confirmation>> |
| Linked risk assessment | <<FILL: RA-ID, e.g. the Formulation Modality Stress Risk Assessment>> |
| Plan owner | <<FILL: e.g. Formulation Development Lead>> |
1. Purpose
This plan defines how formulation development for <<FILL: product>> proceeds from excipient and stress screening through a locked formulation ready for tech transfer, so every excipient, buffer, and presentation choice traces to this modality’s actual dominant degradation mechanism and to measured thermal or stability data, not to what worked on a prior program of a different modality.
2. Scope
| Dimension | Decision |
|---|---|
| Product / modality in scope | <<FILL>> |
| Development stage covered by this plan | <<FILL>> |
| Candidate presentations under evaluation | <<FILL: liquid frozen / liquid refrigerated / lyophilized>> |
| Target route and administration constraint | <<FILL: e.g. subcutaneous, roughly 1 to 2 mL manual-injection ceiling>> |
| Out of scope | <<FILL: e.g. commercial-scale process characterization, covered under a separate tech transfer plan>> |
3. Roles and responsibilities
| Role | Responsibility |
|---|---|
| Formulation scientist / lead | Owns excipient and buffer selection, stress and stability study design, and the presentation decision rationale |
| Analytical development | Builds and validates the stability-indicating, particle-characterization, and, for a viral vector, genome-integrity methods this plan depends on |
| Device / combination product engineer | Owns fill system compatibility and delivery device fit once a high-concentration or prefilled syringe presentation is in scope |
| Manufacturing sciences / tech transfer | Qualifies the scale-down mixing model and carries the locked formulation and process-parameter ranges into transfer |
| QA / Regulatory CMC | Confirms the data package supports the intended specification, expiration dating claim, and container closure strategy |
4. Development approach and stage gates
| Stage | Activity | Exit criterion |
|---|---|---|
| 1. Failure-mode screening | Identify the modality’s dominant degradation mechanism(s) using the linked risk assessment; select candidate excipients and buffers targeted at that mechanism, not a generic panel | Risk assessment approved; screening excipient/buffer matrix defined |
| 2. Lead formulation selection | Execute the screening study (forced degradation, thermal characterization, or design-of-experiments as appropriate to the modality); narrow to one or a small number of lead candidates | Lead formulation(s) selected with documented rationale against the dominant stress |
| 3. Presentation decision | Generate real-time and accelerated stability data on the lead candidate as a liquid; decide liquid versus lyophilized against the criteria in section 6 | Presentation decision documented and approved |
| 4. Confirmation and lock | Execute the confirmatory freeze-thaw, cryoformulation, or lyophilization cycle-development study; qualify the scale-down mixing model | Formulation and process parameters locked; ready for tech transfer risk assessment |
Do not begin Stage 2 candidate narrowing before Stage 1’s risk assessment is approved; a screening matrix built before the dominant failure mode is named routinely tests the wrong variables.
5. Risk basis
This plan executes against <<FILL: risk assessment document number>>, which scores the modality-specific stresses this program is exposed to. Any stress scored at a risk priority of 12 or higher there gets a specific study in section 7, not a general assurance in this plan.
6. The presentation decision
Decide liquid versus lyophilized from the lead candidate’s own data, not from what a prior program used:
| Question | If the answer is yes |
|---|---|
| Is the modality cell-based, or a naked oligonucleotide with no lyophilization-compatible excipient system? | Lyophilization is not a realistic candidate; develop the frozen-liquid or refrigerated-liquid path only |
| Does real-time and accelerated stability support the target shelf life as a liquid, and can the intended cold chain reliably hold the required condition? | A liquid presentation is preferred; document the decision and skip lyophilization cycle development |
| Does the liquid form show a degradation pathway, chemical instability or aggregation, that no achievable storage temperature controls to the target shelf life? | This is the case that justifies lyophilization; proceed to thermal characterization (Tg’, Tc, or eutectic temperature) and cycle design |
| Is this a viral vector program considering lyophilization? | Treat it as its own dedicated development stream: vector-specific thermal characterization and demonstrated infectious titer retention through the full freeze, dry, and reconstitution sequence, not an extension of protein lyophilization data |
7. Studies and deliverables
| # | Study / deliverable | Applies when | Owner | Status |
|---|---|---|---|---|
| 1 | Modality stress risk assessment | Always | <<FILL>> | <<FILL>> |
| 2 | Excipient / buffer screening study | Always | <<FILL>> | <<FILL>> |
| 3 | Forced degradation / stress study | Protein, oligonucleotide, viral vector | <<FILL>> | <<FILL>> |
| 4 | Cryoformulation freeze-thaw study | Cell, viral vector, any frozen-liquid presentation | <<FILL>> | <<FILL>> |
| 5 | Thermal characterization (Tg’/Tc/eutectic) and cycle design | Lyophilized presentation only | <<FILL>> | <<FILL>> |
| 6 | High-concentration / PFS readiness assessment | Subcutaneous, high-concentration programs only | <<FILL>> | <<FILL>> |
| 7 | Scale-down mixing model qualification | Always | <<FILL>> | <<FILL>> |
| 8 | Formulation development report | Always | <<FILL>> | <<FILL>> |
Each deliverable needs a named owner and a tracked status; “in progress” with no owner is not a status.
8. Acceptance criteria for lock
Formulation lock requires: the presentation decision in section 6 documented against real data; every stress scored 12 or higher in the linked risk assessment carrying a mitigation traced to a specific study in section 7; the scale-down mixing model qualified against full-scale or representative-scale data; and, for a lyophilized presentation, a primary and secondary drying design with the product temperature held below the measured Tg’ or Tc (or a documented, characterized rationale for drying above Tg’ but below Tc). A formulation is not locked on stability data alone if the mixing model or, where applicable, the cycle design has not been separately qualified.
9. Timeline and gates
| Gate | Milestone | Target | Actual |
|---|---|---|---|
| G1 | Risk assessment approved, screening matrix defined | <<FILL>> | <<FILL>> |
| G2 | Lead formulation selected | <<FILL>> | <<FILL>> |
| G3 | Presentation decision documented | <<FILL>> | <<FILL>> |
| G4 | Formulation locked, ready for tech transfer | <<FILL>> | <<FILL>> |
10. References
ICH Q8(R2), Pharmaceutical Development. ICH Q5C, Quality of Biotechnological Products: Stability Testing. ICH Q9(R1), Quality Risk Management. USP General Chapter <1207>, Container Closure Integrity.
Confirm the current version of each reference before issue.
11. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
12. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Formulation lead) | <<FILL>> | ||
| Analytical Development | <<FILL>> | ||
| Quality Assurance | <<FILL>> |
Filled specimen
Extract from the plan for Acme Therapeutics’ ATX-AAV9, an AAV9 gene therapy vector entering Stage 3, the presentation decision, after Stage 1 and 2 screening identified capsid rupture and surface adsorption during freeze-thaw as the dominant risk.
| Field | Entry |
|---|---|
| Modality | Viral vector (AAV9) |
| Development stage entering this plan | Presentation lock |
| Candidate presentations under evaluation | Liquid, frozen at -70C |
Stage 2 screening selected a lead formulation carrying a low-level nonionic surfactant and sucrose at a reduced buffer concentration, based on differential scanning fluorimetry ranking of candidate buffer and excipient conditions by apparent capsid melting temperature. Section 6’s presentation questions were answered in sequence: not cell-based or a lyophilization-incompatible oligonucleotide; frozen-liquid stability data supported the target shelf life and the intended dry-vapor shipper cold chain could reliably hold -70C; lyophilization was therefore not pursued for this program, and the fourth question (vector-specific lyophilization) did not apply. The Stage 4 confirmatory freeze-thaw study, executed under the paired freeze-thaw study protocol, read genome leakage (free single-stranded DNA) and infectious titer across three cycles bracketing the worst-case shipping and clinical handling map, not aggregate level alone, and both endpoints met the pre-defined acceptance criteria at cycle three.
Formulation lock was not declared on the freeze-thaw result alone: the scale-down mixing model qualification (deliverable 7) was still open at the time of the Stage 4 result, and lock was held for eleven days until that qualification closed, confirming the bench-scale mixing study predicted full-scale shear exposure within the pre-defined margin.
Common inspection findings this plan prevents
- A presentation decision, liquid versus lyophilized, made on cost or precedent with no documented stability or thermal-characterization basis.
- A formulation declared locked with an open scale-down mixing model qualification, so commercial process-parameter ranges rest on an unproven assumption.
- A viral vector freeze-thaw study reading aggregate level alone, with no genome-leakage endpoint, missing the mechanism the study exists to catch.
- A screening study built before the dominant failure mode is named, testing excipients targeted at the wrong stress for this modality.
- A high-concentration or lyophilization workstream started with no linkage back to the modality stress risk assessment driving it.
How to adapt this plan
- Set your document number, modality, and linked risk assessment number in the header.
- Size section 4 to your actual entry point; a program entering at Stage 3 skips Stage 1 and 2 activities but still documents the basis carried forward from them.
- In section 7, remove rows that do not apply to this modality and add any product-specific study not already listed.
- Answer every question in section 6 with data, in order; do not skip to a lyophilization workstream without first answering whether a liquid presentation is viable.
- Confirm every reference in section 10 against the current published version before issue.